FEBNM
Certificate of Fellowship of the European Board of Nuclear Medicine
Prostate TheranosticsEnglish
Exam overviewPractice session
A 72-year-old man with metastatic castration-resistant prostate cancer is being evaluated for lutetium-177 PSMA radioligand therapy. PSMA PET/CT shows intense uptake in most bone and nodal metastases, but one enlarging liver lesion is PSMA-negative and FDG-positive. What is the main clinical implication?
Loading your practice session…